MedTrace Logo

Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

NCT04366245 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-04-06

No results posted yet for this study

Summary

Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.

Conditions

  • SARS-CoV 2

Interventions

BIOLOGICAL

Hyperimmune plasma

PLASMA OF CONVALESCENT COVID-19

DRUG

Standard of care for SARS-CoV-2 infection

Standard of care for SARS-CoV-2 infection

Sponsors & Collaborators

  • Andalusian Network for Design and Translation of Advanced Therapies

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04366245 on ClinicalTrials.gov